These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12818936)

  • 21. Early assessment of the left ventricular function by epirubicin-induced cardiotoxicity in postoperative breast cancer patients.
    Luo R; Cui H; Huang D; Li G
    Echocardiography; 2017 Nov; 34(11):1601-1609. PubMed ID: 28895191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
    Shipman KE; Arnold I
    J Clin Oncol; 2011 Jun; 29(18):e537-8. PubMed ID: 21482996
    [No Abstract]   [Full Text] [Related]  

  • 23. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
    Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
    J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
    Miller DK; Munshi N; Loesch D; Einhorn LE; Sledge GW
    Cancer; 2000 Jan; 88(2):375-80. PubMed ID: 10640971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy during pregnancy: what is really safe?
    Peccatori F; Martinelli G; Gentilini O; Goldhirsch A
    Lancet Oncol; 2004 Jul; 5(7):398. PubMed ID: 15231245
    [No Abstract]   [Full Text] [Related]  

  • 28. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
    Ciotti R; Ucci G; Belotti G; Facchi E; Cremonesi M; Gatti C; Baccheta G
    J Clin Oncol; 2001 Nov; 19(22):4269-70. PubMed ID: 11709572
    [No Abstract]   [Full Text] [Related]  

  • 29. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 30. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
    Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
    Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
    Banke A; Fosbøl EL; Møller JE; Gislason GH; Andersen M; Bernsdorf M; Jensen MB; Schou M; Ejlertsen B
    Eur J Heart Fail; 2018 Oct; 20(10):1447-1453. PubMed ID: 29493047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
    Barni S; Piazza E; Frontini L; Visini M; Ardizzoia A; Grassi MM; Nosenzo MA; Mandalà M; Biasioli R; Freddi E; Lucani L; Recalcati A; Pravettoni A; Sala R; Rezzani C; Villa S; Trabucchi E;
    Oncology; 2004; 67(1):40-7. PubMed ID: 15459494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
    Lehnert M; Mross K; Schueller J; Thuerlimann B; Kroeger N; Kupper H
    Br J Cancer; 1998 Apr; 77(7):1155-63. PubMed ID: 9569055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables.
    Tjeerdsma G; Meinardi MT; van Der Graaf WT; van Den Berg MP; Mulder NH; Crijns HJ; de Vries EG; van Veldhuisen DJ
    Heart; 1999 Apr; 81(4):419-23. PubMed ID: 10092570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Images in clinical medicine. Extravasation of epirubicin.
    Vano-Galvan S; Jaen P
    N Engl J Med; 2009 May; 360(20):2117. PubMed ID: 19439746
    [No Abstract]   [Full Text] [Related]  

  • 36. Epirubicin for breast cancer may cause considerable venous sclerosis.
    Bolton-Maggs P; Flavin A
    BMJ; 2005 Oct; 331(7520):816. PubMed ID: 16155047
    [No Abstract]   [Full Text] [Related]  

  • 37. Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.
    Framarino-dei-Malatesta M; Perrone G; Giancotti A; Ventriglia F; Derme M; Iannini I; Tibaldi V; Galoppi P; Sammartino P; Cascialli G; Brunelli R
    BMC Cancer; 2015 Dec; 15():951. PubMed ID: 26673573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
    Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
    Heart; 2002 Jul; 88(1):81-2. PubMed ID: 12067953
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of early epirubicin cardiotoxicity in women with breast cancer.
    Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S
    Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines.
    Radulescu D; Pripon S; Radulescu LI; Duncea C
    Acta Cardiol; 2008 Feb; 63(1):27-32. PubMed ID: 18372577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.